Table 3 HPLC methods for analysis of FDA-approved treatments for several cardiovascular illnesses from 2015 to June 2020
Stationary phase | Mobile Phase (v/v) | Detection (nm) | Applications |
|---|---|---|---|
X-bridge phenyl column | 0.1% formic acid: Acetonitrile (50:50) | 300 | Characterization of process related impurities including degradation products of selexipag (Amara Babu et al. 2021) |
C-18 column | Acetonitrile: Water (95:5) | 254 | Determination of sacubitril in bulk and dosage forms (Moussa et al. 2018) |
C-18 column | Acetonitrile: Triethylamine buffer (50:50) | 239 | Determination of sacubitril in tablets (Mishra et al. 2020) |
C-18 column | OPA (0.1%): Acetonitrile (60:40) | 254 | Estimation of sacubitril in bulk and pharmaceutical dosage forms (Tohidi et al. 2019) |
C-18 column | Water: Methanol (30:70) | 254 | Determination of sacubitril in tablets (Phalguna et al. 2018) |
C-18 column | Methanol | 254 | Determination of sacubitril in bulk dosage forms (Trefi et al. 2019) |
OJ-H Column | n-hexane 0.1%: TFA (80:20) | 254 | Determination of stereoisomers of sacubitril in bulk dosage forms (Zhou et al. 2018) |
C-18 column | Methanol: Water (60:40) | 245 | Determination of sacubitril in tablets (Kumar et al. 2021) |
C-18 column | Acidified water (pH 3, adjusted with Acetic acid: Acetonitrile (55:45) | 254 | Determination of sacubitril in rat plasma (Moussa et al. 2018) |
C-18 column | Methanol:Ethanol:Water (40:30:30) | 254 | Estimation of sacubitril in human plasma and in tablets (Alamein and AM. 2018) |
C-18 column (LC) | Methanol: Water (80:20) | 241 | Estimation of sacubitril in bulk and pharmaceutical dosage forms (Vaka and Parthiban 2017) |
C-18 column | Acetonitrile:Methanol:Potassium dihydrogen phosphate (30:50:20) | 263 | Forced degradation study of sacubitril in tablets (Naazneen and Sridevi 2017) |
C-18 column | Acetonitrile:Potassium hydrogen phosphate (30:70) | 371 | Determination of sacubitril in rat plasma (Anjaneyulu et al. 2018) |
C-8 column (UHPLC) | THF:Water:Acetonitrile (5:15:80) as ingredient mode | 240 | Determination of sacubitril in tablets (Prajapati et al. 2020) |
C-18 column (LC-UV) | 0.2% Formic acid | 285 | Characterization of Cangrelor IV (Guvvala et al. 2019) |
ODS-3 V Column | 0.5% Formic acid: Acetonitrile (65:35) | 286 | Determination of ivabradine HCl in tablets (Maheshwari et al. 2010) |
C-18 column | Phosphate buffer (pH 7.4): Methanol (35:65) | 286 | Determination of ivabradine HCl in formulation (Patra and Panda 2014) |
C-8 column | Acetonitrile:20 mmol ammonium acetate (40:60) | 207 and 286 | Determination of dual wavelength in ivabradine tablets (Nowakowska et al. 2017) |
C-18 column | Methanol: Acetonitrile (80:20) | 286 | Estimation of ivabradine HCl in bulk and dosage forms (Thete and Saudagar 2019) |
C-18 column | Methanol: Acetonitrile: Phosphate buffer (pH 3) (50:40:10) | 230 | Determination of ivabradine HCl in tablets (Mostafa et al. 2016) |
C-18 column | Methanol: Acetonitrile (85:15) | 291.2 | Determination of edoxaban HCl in bulk and dosage forms (Sankar et al. 2021) |
C-18 column | 0.1% Formic acid water: Acetonitrile (80:20) | 291.2 | Determination of edoxaban HCl in powder inhaler formulation (Rashid et al. 2021) |
C-18 column | Methanol: Acetonitrile (85:15) | 291 | Rapid assay therapeutic drug monitoring of edoxaban (Rashid et al. 2022 Apr 17) |
C-18 column | Acetonitrile: Water (90:10) | 249 | Determination of edoxaban HCl in human plasma (Gouveia et al. 2020) |
C-8 column | Methanol: Phosphate buffer (pH 4) | 290 | Determination of edoxaban HCl in human plasma (Younis et al. 2020) |
C-18 column | 0.1 M K2HPO4: Methanol (65:35) | 245 | Determination of edoxaban HCl in bulk and dosage forms (Reddy et al. 2016 ) |
C-18 column | Potassium dihydrogen phosphate:Acetonitrile (30:70) | 230 | Determination of edoxaban HCl in bulk and dosage forms (Banda 2022) |
C-18 column | 0.01 m sodium acetate (pH 4): Acetonitrile (70:30) | 290 | Determination of edoxaban HCl in bulk and dosage forms (Todkar et al. 2020) |
C-18 column | Acetonitrile:Methanol:Water (35:35:30) | 240 | Determination of betrixaban in pharmaceuticals and biological matrixes (El-Masry et al. 2021) |
RP-18 | 0.1% trifluoroacetic acid with water:Acetonitrile (42:58) | 280 | Determination of tafamidis in plasma concentration in patients (Smerikarova et al. 2021) |
C-18 column | KH2PO4: Acetonitrile (55:45) | 246 | Determination of bempedoic acid in bulk and dosage forms (Maheshwari and Rani 2022) |
C-18 column (RP-UPLC) | Methanol:Acetonitrile:Water (50:30:20) | 260 | Stability indicating estimation of bempedoic acid in bulk and dosage forms (Yarra and Gummadi 2021) |
C-18 column (RP-UPLC) | 0.1% TFA in water:Acetonitrile (60:40) | 236 | Stability indicating estimation of bempedoic acid in bulk and dosage forms (Dandamudi and Rangapuram 2021) |
C-18 column (HPLC–PDA) | 0.1% TFA in water: Acetonitrile (40:60) | 236 | Determination of bempedoic acid in rat plasma (Karla et al. 2022) |
C-18 column (UPLC) | 0.1% OPA:Acetonitrile (50:50) | 230 | Determination of degradation products of bempedoic acid (Vejendla et al. 2021) |
C-18 column | Ammonium formate:acetonitrile ( 57:43) | 250 | Determination of valsartan in nanoparticles (Alexander and Kumar 2018) |
C-18 column | Acetate buffer (pH 4.6): acetonitrile: methanol (38:24:38) | 248 | Estimation of valsartan in solid oral dosage form (Tarkase et al. 2020) |
C-18 column | Acetonitrile:Phosphate buffer (52:48) | 255 | Valsartan quantification in human plasma (Tammam and Talib 2019) |
C-18 column | Acetonitrile:Water:Glacial acetic acid (40:59:1) | 264 | Determination of valsartan in biological fluid (Ghayas et al. 2017) |
C-18 column | Acetonitrile: Phosphate buffer (adjusted to pH 2.7 ± 0.1 with phosphoric acid) (45:55) | 265 | Determination of valsartan in human plasma (Pérez et al. 2017) |
RP-C18 column | Acetonitrile: Phosphate buffer (0.05 M) with pH 2.8 (40/60) | 227 | Estimation of Valsartan in Dosage Form and Spiked Human Plasma (EL-Gizawy SM, Abdelmageeb OH, Omar MA, Deryea SM, Abdel-Megieb AM 2012) |
RP-18 column | 0.01 M disodium hydrogen phosphate buffer: acetonitrile (60:40) | 230 | Estimation of Valsartan in Human Plasma (Zarghi et al. 2008) |
C-18 column (RP-UPLC) | The solvent A:1.0% acetic acid buffer, Acetonitrile (90:10): Solvent B1.0% acetic acid buffer and acetonitrile (10:90) | 225 | Valsartan and its degradation products' estimation in active medicinal ingredients and dose forms (Krishnaiah et al. 2010) |
C-18 column | Ammonium dihydrogen phosphate: methanol (33.5:66.5) | 265 | Stability indicating estimation of valsartan in tablet dosage form (Parambi et al. 2011) |
C-18 column | 0.02 mM sodium dihydrogen orthophosphate acetonitrile (58:42) | 250 | Stability indicating estimation of valsartan in tablet dosage form (Rao et al. 2010) |
C-18 column (Isocratic) | Methanol: Water (60:40) | 250 | Estimation of valsartan and its degradation products (Bhatia and Kokil 2009) |
C-18 column | Water: Acetonitrile (60:40) | 265 | Inherent stability estimation of valsartan by stress degradation (Agrahari et al. 2009) |